Trevi Therapeutics, Inc.
Trevi Therapeutics is a clinical-stage biopharmaceutical company developing Haduvio, an oral extended-release formulation of nalbuphine, to treat chronic cough in patients with idiopathic pulmonary fibrosis, other interstitial lung diseases and refractory chronic cough. Haduvio acts on kappa- and mu-opioid receptors involved in the cough reflex. Trevi’s programs include clinical trials for these three patient groups, along with Phase 1 studies to support potential regulatory submissions. Haduvio is investigational and is not described as an approved treatment for chronic cough. Trevi retains worldwide commercial rights to Haduvio and licenses rights to nalbuphine from Keenova Therapeutics. It contracts with third parties to supply nalbuphine hydrochloride drug substance and manufacture Haduvio tablets for clinical trials. Trevi is headquartered in New Haven, Connecticut.
No enriched coverage for $TRVI in the last 7 days.
No SEC Form 4 filings for $TRVI in the last 30 days.
See all $TRVI insider activity →Trevi Therapeutics (TRVI) announced that Phase 2b CORAL trial results for nalbuphine ER in treating chronic cough in IPF patients will be presented at CHEST 2026. The trial showed early, sustained improvement in patient-reported outcomes. Trevi is developing Haduvio (nalbuphine ER) for chronic cough in IPF, non-IPF ILD, and RCC, areas with high unmet medical need.
BMO Capital reiterated an Outperform rating and $36.00 price target for Trevi Therapeutics (TRVI) after a competitor's trial failed. The stock is down ~8% over the past week. Trevi's drug candidate, Haduvio, has central and peripheral activity, with clinical readouts expected in late 2027. The company reported a wider-than-expected Q2 2026 loss but has sufficient cash to fund operations until 2030, according to the company.
Heffernan Michael Thomas sold 39,473 shares of Trevi Therapeutics, Inc. (TRVI) at an average of $15.09 ($15.09–$15.88, $0.60M total) across 4 trades on 2026-09-15 under a Rule 10b5-1 trading plan.
Recent TRVI coverage spans financial news, technology and insider activity.
Conference-accepted PRO results are likely to reinforce bullish sentiment around Haduvio’s clinical profile in IPF-related chronic cough, though they are not a regulatory decision.
Analyst upgrades and competitor failure suggest upside potential for TRVI.
The insider sale may exert slight downward pressure on TRVI stock.
Advancement to Phase III suggests higher probability of product approval, which could boost stock valuation.
Trial kickoff and stated funding runway support a bullish re-rating narrative, but the article flags ongoing losses and possible dilution risk.
AlphAI scores every news story that mentions TRVI with an AI model for sentiment and relevance, and aggregates insider trades from Trevi Therapeutics, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Trevi Therapeutics (TRVI) announced that Phase 2b CORAL trial results for nalbuphine ER in treating chronic cough in IPF patients will be presented at CHEST 2026. The trial showed early, sustained improvement in patient-reported outcomes. Trevi is developing Haduvio (nalbuphine ER) for chronic cough in IPF, non-IPF ILD, and RCC, areas with high unmet medical need.
3 min readBMO Capital reiterated an Outperform rating and $36.00 price target for Trevi Therapeutics (TRVI) after a competitor's trial failed. The stock is down ~8% over the past week. Trevi's drug candidate, Haduvio, has central and peripheral activity, with clinical readouts expected in late 2027. The company reported a wider-than-expected Q2 2026 loss but has sufficient cash to fund operations until 2030, according to the company.
2 min readHeffernan Michael Thomas sold 39,473 shares of Trevi Therapeutics, Inc. (TRVI) at an average of $15.09 ($15.09–$15.88, $0.60M total) across 4 trades on 2026-09-15 under a Rule 10b5-1 trading plan.
1 min readTrevi Therapeutics (TRVI) reported phase III trials for chronic cough treatment, targeting unmet needs. The company's nalbuphine drug has a unique mechanism and strong IP, with funding secured until early 2030, according to a Morgan Stanley conference presentation.
2 min readSimply Wall St reports Trevi Therapeutics (TRVI) has started Phase 3 and Phase 2B chronic cough trials and says it has about $188M in cash, cash equivalents and marketable securities at year-end 2025, supporting a runway into 2028. The article cites TRVI shares at $18.50 and a fair value narrative of $26.18.
6 min readTrevi Therapeutics, Inc. (TRVI) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Trevi Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Updates Initiated Phase 3 OCEAN-1 trial for patients with idiopathic pulmonary fibrosis-related chronic cough in the second quarter; Phase 3 OCEAN-2 trial expected to initiate in t
7 min readAnalysts initiated coverage on several stocks. BMO Capital began coverage of Insmed (NASDAQ:INSM) with an Outperform rating and $192 target, and Axsome Therapeutics (NASDAQ:AXSM) with an Outperform rating and $310 target. Compass Point started American Healthcare REIT (NYSE:AHR) at Buy with $70 target. BMO initiated Trevi Therapeutics (NASDAQ:TRVI) at Outperform with $36 target, and Rodman & Renshaw started Eledon Pharmaceuticals (NASDAQ:ELDN) at Buy with $12 target.
2 min readTrevi Therapeutics (NASDAQ:TRVI) shares rose 9.85% to $19.07 after management highlighted clinical results for Haduvio, an extended-release nalbuphine oral treatment for refractory chronic cough (RCC) and idiopathic pulmonary fibrosis (IPF). The company cited a $14B to $15B chronic cough market by 2035. It plans a Phase 2b trial in 2H 2026.
5 min readGSK plc reported phase III results for camlipixant, a P2X3 receptor antagonist, from the Calm-1 and Calm-2 trials. According to GSK, the Calm-1 trial met its primary endpoint, with 50 mg twice daily reducing 24-hour cough frequency versus placebo at week 12. GSK’s walk-away from the program also highlighted Trevi Therapeutics’ Haduvio, which had positive phase II data in June.
4 min readTrevi Therapeutics shares rose 13.10% to $19.64 after the company presented clinical data on Haduvio (nalbuphine extended-release) for chronic cough at the European Respiratory Society Cough Conference in London. Trevi said results show a statistically significant cough-frequency reduction across IPF-related and refractory chronic cough. Analysts cited a $21.10 average target; Trevi also reported a June $162 million net offering.
6 min read
